Form 4: ATAI Life Sciences N.V. Reports Sale of Compass Pathways Shares

ATAI Life Sciences N.V. reports the sale of 2,660,000 Ordinary Shares of Compass Pathways plc at $6.05 per share on September 26, 2024.

Summary

• ATAI Life Sciences N.V., along with its subsidiary ATAI Life Sciences AG, filed a Form 4 with the SEC.
• The report details a transaction on September 26, 2024, where ATAI Life Sciences AG disposed of 2,660,000 Ordinary Shares of COMPASS Pathways plc (CMPS).
• The shares were sold at a price of $6.05 per share.
• Following the transaction, ATAI Life Sciences N.V. indirectly beneficially owns 6,905,774 Ordinary Shares through its subsidiary ATAI Life Sciences AG.

Sentiment

Score: 4

Explanation: The sentiment is neutral to slightly negative. A large shareholder selling a significant portion of their shares can be interpreted negatively by the market, but the document itself is simply reporting a transaction.

Negatives

• ATAI Life Sciences N.V. has reduced its stake in Compass Pathways plc by selling 2,660,000 shares.

Risks

• The sale of shares by a major shareholder like ATAI Life Sciences N.V. could potentially exert downward pressure on the stock price of Compass Pathways plc (CMPS).

Industry Context

ATAI Life Sciences is a significant investor in the mental health space, and its actions regarding its holdings in companies like Compass Pathways are closely watched by investors in the psychedelic medicine industry.

Stakeholder Impact

• Shareholders of Compass Pathways plc (CMPS) may react to the news of ATAI Life Sciences N.V.'s share sale.

Key Dates